郑州微飒生物科技有限责任公司 咨询热线：0371-88821766
行业动态

行业动态

追踪行业前沿，洞察产业趋势

药效评价Functional and binding kinetic studies make a distinction between OX1 and OX2 orexin receptor antagonists.

期刊：European journal of pharmacology发表年份：2012作者：Stefania Faedo; Elisabetta Perdonà; Marinella Antolini; Romano di Fabio; Emilio Merlo Pich; Mauro Corsi
阅读更多 →

药效评价Discovery of (2S,3R)-N-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]benzo[b]furan-2-carboxamide (TC-5619), a selective α7 nicotinic acetylcholine receptor agonist, for the treatment of cognitive disorders.

期刊：Journal of medicinal chemistry发表年份：2012作者：Anatoly A Mazurov; David C Kombo; Terry A Hauser; Lan Miao; Gary Dull; John F Genus; Nikolai B Fedorov; Lisa Benson; Serguei Sidach; Yunde Xiao; Philip S Hammond; John W James; Craig H Miller; Daniel Yohannes
阅读更多 →

药效评价No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease.

期刊：Neurobiology of aging发表年份：2012作者：Antje Hillmann; Stefanie Hahn; Stephan Schilling; Torsten Hoffmann; Hans-Ulrich Demuth; Bruno Bulic; Thomas Schneider-Axmann; Thomas A Bayer; Sascha Weggen; Oliver Wirths
阅读更多 →

药效评价Optimization of 5-pyridazin-3-one phenoxypropylamines as potent, selective histamine H₃ receptor antagonists with potent cognition enhancing activity.

期刊：Journal of medicinal chemistry发表年份：2012作者：Ming Tao; Lisa D Aimone; Zeqi Huang; Joanne Mathiasen; Rita Raddatz; Jacquelyn Lyons; Robert L Hudkins
阅读更多 →